How Hims & Hers Reached a $4.3BN Market Cap on $2.3BN of Revenue | Andrew Dudum
Andrew Dudum, CEO of Hims & Hers, discusses how the telemedicine platform reached a $4.3B valuation despite a 66% stock decline, and how his company is reshaping healthcare distribution by making treatments affordable and accessible. Dudum reveals his philosophy on hiring crisis-tested teams, managing aggressive growth through acquisitions, and building a preventative health platform that competes with traditional healthcare infrastructure rather than competing on price alone.
Key takeaways
- • Hire people who've survived chaos, not credentialed resume-builders—Dudum's CFO navigated Uber's COVID collapse and his CPO managed the GameStop/Robinhood crisis, proving that grit and adaptability outperform pedigree when disrupting industries.
- • Build your team to replace yourself every 12 months by hiring people smarter than you in each function, then deliberately get deep only on strategic initiatives—avoid the trap of reviewing everything, which prevents scaling and signals weak leadership to talented hires.
- • Running a public company is more fun than private for competitive builders because quarterly benchmarks force discipline, talent is attracted to measurable vision, and you're forced to prove progress incrementally like the early growth days of Google, Apple, and Amazon.
- • Brand consistency matters more than novelty—say the same message 20 different ways across multiple channels repeatedly; early companies fail by rotating messaging quarterly, but great brands win by boring repetition that builds cultural zeitgeist and trust over years.
- • Don't be first to market, be best to market—Dudum plans to enter peptides (BPC-157, TB-500) only when clinical protocols, supply chains, and quality controls are bulletproof, applying pressure on drug manufacturers to reduce prices from $1,800 to $149 for GLP-1s within 18 months.
- • Offer loss-leader diagnostics to build data and loyalty—Hims is verticalizing blood collection devices and lab infrastructure to eventually offer 50-biomarker panels free with membership, making prevention accessible and turning patients into lifelong customers before they ever need treatment.
- • Aggressive M&A works if you stay uncomfortable—Dudum acquired Eucalyptus (Australia/UK digital health leader) for ~$1.5B and completed three major deals internationally; the key is hiring teams trained in chaos, constantly questioning strategy, and sitting in that discomfort rather than pulling back.
Recommendations (4)
"this is a test that I've been taking for 5 years. I've had everyone in my family take because there's there's cancer in my family. It's called the gallery test by Grail"
Andrew Dudum · ▶ 19:55
"they're hearing about it through, you know, watching Fox News"
Andrew Dudum · ▶ 28:44
Mentioned (22)
More from these creators
OpenAI Kills Sora & Hits $100M ARR on Ads | Oura Going Public & Whoop Raises at $10BN
Why Margins Don't Matter for Early-Stage Startups | Gili Raanan
Why You Need a $1B Fund To Do Series A | SpaceX at $2TRN & Data Centers in Space | Groq's $20BN Deal
99% of Drone Companies Will Die & Why Anduril’s Products Aren’t an Ethics Debate | Matthew Steckman
Inside Figma's $1B ARR Machine | Shaunt Voskanian
NVIDIA Predicts $1TRN in Revenue: Everything You Need to Know From GTC & Anduril Lands $20B Contract